Company Analysis
Sign in

Collegium Pharmaceutical, Inc. (COLL)

Nasdaq: COLL · Pharmaceutical Preparations · Stoughton, MA · filing with the SEC since 2003
Full chart Alerts Compare
Grade6.4
◀ Past 7.8● Present 6.1▶ Future 5.4
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

60 patents granted to the 7 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Collegium Pharmaceutical, Inc.’s names, not what it holds today.

Patents granted
60
60 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and none in 2023
Applications published
174
2 of them in 2025
Names they are printed under
7
a subsidiary, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name7 counted
BioDelivery Sciences International, Inc. a subsidiary
US, as the owner printed on each patent
9 granted
69 published
Collegium Pharmaceutical, Inc. its own name
US, as the owner printed on each patent
28 granted
43 published
Ironshore Pharmaceuticals & Development, Inc. a subsidiary
KY, as the owner printed on each patent. 1 more under the same name are not counted (printed in US)
22 granted
3 published
Ironshore Pharmaceuticals & Development, Inc. a subsidiary
named as the applicant on its applications, in KY. 1 more under the same name are not counted (printed in US)
0 granted
23 published
Collegium Pharmaceutical, Inc. its own name
named as the applicant on its applications, in US. 1 more under the same name are not counted (printed in KY)
0 granted
20 published
BioDelivery Sciences International, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
15 published
Arius Two, Inc. a subsidiary
US, as the owner printed on each patent
1 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 12, 202512,383,506Compositions for treatment of attention deficit hyperactivity disorderPharmaceuticalsIronshore Pharmaceuticals & Development, Inc.
Feb 27, 202411,911,518Compositions for treatment of attention deficit hyperactivity disorderPharmaceuticalsIronshore Pharmaceuticals & Development, Inc.
Feb 8, 202211,241,392Compositions for treatment of attention deficit hyperactivity disorderPharmaceuticalsIronshore Pharmaceuticals & Development, Inc.
Feb 8, 202211,241,391Compositions for treatment of attention deficit hyperactivity disorderPharmaceuticalsIronshore Pharmaceuticals & Development, Inc.
Feb 2, 202110,905,652Compositions for treatment of attention deficit hyperactivity disorderPharmaceuticalsIronshore Pharmaceuticals & Development, Inc.
Jan 5, 202110,881,618Compositions for treatment of attention deficit hyperactivity disorderPharmaceuticalsIronshore Pharmaceuticals & Development, Inc.
Jun 2, 202010,668,060Tamper-resistant pharmaceutical compositions of opioids and other drugsPharmaceuticalsCollegium Pharmaceutical, Inc.
May 12, 202010,646,485Process of making stable abuse-deterrent oral formulationsPharmaceuticalsCollegium Pharmaceutical, Inc.
Apr 14, 202010,617,651Compositions for treatment of attention deficit hyperactivity disorderPharmaceuticalsIronshore Pharmaceuticals & Development, Inc.
Jan 7, 202010,525,053Abuse-deterrent pharmaceutical compositions of opioids and other drugsPharmaceuticalsCollegium Pharmaceutical, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 3, 20252025/0213554PROCESS OF MAKING STABLE ABUSE-DETERRENT ORAL FORMULATIONSPharmaceuticalsCollegium Pharmaceutical, Inc.
Feb 27, 20252025/0064796ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINEPharmaceuticalsBioDelivery Sciences International, Inc.
Aug 8, 20242024/0261278ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINEPharmaceuticalsBioDelivery Sciences International, Inc.
Jul 11, 20242024/0226023Compositions for Treatment of Attention Deficit Hyperactivity DisorderPharmaceuticalsIronshore Pharmaceuticals & Development, Inc. · patent 12,383,506 granted from it
Jul 11, 20242024/0225998TRANSMUCOSAL DRUG DELIVERY DEVICES FOR USE IN CHRONIC PAIN RELIEFPharmaceuticalsBioDelivery Sciences International, Inc.
May 23, 20242024/0165102ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINEPharmaceuticalsBioDelivery Sciences International, Inc.
May 16, 20242024/0156809TRANSMUCOSAL DELIVERY DEVICE WITH ENHANCED UPTAKEPharmaceuticalsBioDelivery Sciences International, Inc.
May 9, 20242024/0148639TRANSMUCOSAL DRUG DELIVERY DEVICES FOR USE IN CHRONIC PAIN RELIEFPharmaceuticalsBioDelivery Sciences International, Inc.
Apr 25, 20242024/0130961TRANSMUCOSAL DRUG DELIVERY DEVICES FOR USE IN CHRONIC PAIN RELIEFPharmaceuticalsBioDelivery Sciences International, Inc.
Apr 18, 20242024/0122920PROCESS OF MAKING STABLE ABUSE-DETERRENT ORAL FORMULATIONSPharmaceuticalsCollegium Pharmaceutical, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 12.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton COLL · research, not advice